01875nam a2200253   4500001000800000005001700008007000300025008004100028040000800069041000800077100004000085245003200125300002500157520113700182650001801319650003301337650001901370650003501389650002201424650001701446773011001463942003101573999001701604ESSALUD20260903101044.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aGreenberg, Steven M. eAutor954526  aCerebral amyloid angiopathy  apáginas: 1836-1845  aCerebral amyloid angiopathy is a major cause of hemorrhagic stroke, a frequent contributor to age-related cognitive impairment, and a key component in adverse responses to beta-amyloid (Aβ) immunotherapy. Defined by pathological deposition of Aβ in the small blood vessels of the brain, cerebral amyloid angiopathy is most often diagnosed on the basis of magnetic resonance imaging studies showing multiple hemorrhages or leptomeningeal blood products within or overlying the cerebral cortex. The disorder typically manifests as hemorrhagic stroke or as a contributing factor to cognitive decline and, less commonly, with transient focal neurologic symptoms or a cerebral inflammatory autoimmune syndrome. The high risk of recurrent hemorrhagic strokes associated with cerebral amyloid angiopathy poses a particular challenge in patients with indications for antithrombotic therapy and dictates a carefully individualized weighing of risks and benefits. Ongoing research is focused on tools to aid in risk prediction, early diagnostic markers, and identification of key pathogenic steps as targets for disease-modifying therapies.  aALERGIA97055  aENFERMEDAD AUTOINMUNE953665  aDEMENCIA98165  aENFERMEDAD DE ALZHEIMER 95521  aGERIATRÍA91852  aICTUS9544580 022717922676dMassachusetts NEJM GroupoNEJM015tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-31zsqb  c22919d22919